2025-06-12-Jefferies-泰莎基因疗法公司（TSHA）_IRSF_25会议演讲及与关键意见领袖对话的要点_8页_119kb

Summary of Taysha Gene Therapies (TSHA) Equity Research Report

• Company Overview: Taysha Gene Therapies, founded in 2019 as a joint venture with the University of Texas Southwestern Medical Center, develops AAV-based gene therapies for central nervous system (CNS) disorders. Its lead asset, TSHA-102, is in clinical development for Rett syndrome.

• Rating and Price Target: The equity research assigns a "BUY" rating with a price target of $8.00 per share, a 200% increase from the $2.67 current price. Market capitalization is $719.0 million.

• Key Clinical Data:

  • REVEAL Phase I/II Trial: Updated dataset (n=10, 4 low-dose, 6 high-dose) showed milestone gains across patients. Independent assessment of videos by central raters likely underestimates the full extent, with no plateau in benefits observed. High-dose group showed improvements, including a deep reduction in the R-MBA rating scale (-12.8 at 12 months, a significant positive surprise as it evaluates specific domains with formal psychometrics).
  • NHP Biodistribution: Intrathecal administration demonstrated robust vector genome copy distribution in the brain and spinal cord, with a 1.5-2x increase in high-dose versus low-dose settings, supporting widespread transduction and clinical data.
  • Caregiver Survey: High interest (64% of 233 surveyed) in gene therapy trials, with key priorities including improving fine/gross motor function and communication skills.

• Expert Opinions:

  • Dr. Jeff Neul (KOL) praised the data as "looking good," noting TSHA's deeper R-MBA improvement and less stringent milestone analysis in REVEAL. He discussed limitations in comparing datasets with NGNE due to methodological differences and hesitations related to intracranial ventricular (ICV) administration.
  • Comparison with NGNE: No clear differentiation beyond route of administration; Neul suggested NGNE may have a different bar for families due to ICV delivery concerns. Both therapies show promise for gene therapy trials.

• Market Response and Risks: Caregiver interest supports potential for a fast 3-6 month enrollment timeline for pivotal trials (target n=15). Risks include uncertainties in efficacy, drug-related toxicities, competition, and lack of detailed NGNE methodology. Valuation based on discounted cash flow (DCF) and probability-adjusted earnings per share (EPS), with risks potentially impacting the price target.

• Conclusion: TSHA is recommended as a "BUY" with focus on clinical advancements and market potential, despite inherent risks. Pivotal trial enrollment could accelerate based on current data.